Replies to post #213344 on Anavex Life Sciences Corp (AVXL)

[TempePhil]

George, posts presentations. Interesting that Dr.Kaufmanns presentation on Rett behavior, draws links to Autism, which could be huge for A2-73. Would like to see that trial next! Also, it appears there is nothing A2-73 specific in his presentation...like he stuck to the Behavior title, and did not include the latest anavex trial (6 cohort) results! There was some tongue in cheek question about that early on.

Also regarding presentation by Neul related to Rett trials. He covers Trofinetide, but I cant tell what his charts say about it (they appear to be heavily compressed images). But comparisons of a2-73 vs trifinetide have already been done on this board. A2-73 was twice as good (using the data we have).

Disappointed that Neul did not give clearer efficacy description for the 6 cohort Rett A2-73 trial results. He did have one powerful sentence, but I am afraid it may have been lost in the forest. The sentence said there was an efficacy signal for both clinical and and caregiver measures, with correlation to biomarkers. Again already extensively analyzed and dicussed on this board(kudos to this board again). I would have been interested in his professional opinion of A2-73s signal etc.
Was Neuls data of the Anavex Rett trial results, what we thought Kaufmann would present or am i missing something?

Many thanks George!

[TempePhil]

George, posts presentations. Interesting that Dr.Kaufmanns presentation on Rett behavior, draws links to Autism, which could be huge for A2-73. Would like to see that trial next! Also, it appears there is nothing A2-73 specific in his presentation...like he stuck to the Behavior title, and did not include the latest anavex trial (6 cohort) results! There was some tongue in cheek question about that early on.

Also regarding presentation by Neul related to Rett trials. He covers Trofinetide, but I cant tell what his charts say about it (they appear to be heavily compressed images). But comparisons of a2-73 vs trifinetide have already been done on this board. A2-73 was twice as good (using the data we have).

Disappointed that Neul did not give clearer efficacy description for the 6 cohort Rett A2-73 trial results. He did have one powerful sentence, but I am afraid it may have been lost in the forest. The sentence said there was an efficacy signal for both clinical and and caregiver measures, with correlation to biomarkers. Again already extensively analyzed and dicussed on this board(kudos to this board again). I would have been interested in his professional opinion of A2-73s signal etc.
Was Neuls data of the Anavex Rett trial results, what we thought Kaufmann would present or am i missing something?

Many thanks George!